Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Mallinckrodt
Dow
McKinsey
Baxter

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ATOMOXETINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Atomoxetine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00029614 ↗ Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2006-05-01 The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).
NCT00029614 ↗ Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD Completed University of Pittsburgh Phase 2 2006-05-01 The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).
NCT00089869 ↗ A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia Completed Eli Lilly and Company Phase 1/Phase 2 1969-12-31 Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
NCT00142961 ↗ Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Completed National Institute on Drug Abuse (NIDA) Phase 2 2005-10-01 Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence.
NCT00142961 ↗ Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Completed New York State Psychiatric Institute Phase 2 2005-10-01 Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence.
NCT00161031 ↗ Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia Completed University of Maryland N/A 2004-04-01 The purpose of this study is to: - To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory, working memory, and executive functioning. To determine the effect size of atomoxetine on these neuropsychological measures for follow-up studies. - To determine if atomoxetine has short-term benefits for improving weight gain and other metabolic abnormalities associated with antipsychotics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atomoxetine Hydrochloride

Condition Name

Condition Name for Atomoxetine Hydrochloride
Intervention Trials
Attention Deficit Hyperactivity Disorder 66
Attention Deficit Disorder With Hyperactivity 15
ADHD 14
Attention-Deficit/Hyperactivity Disorder 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atomoxetine Hydrochloride
Intervention Trials
Attention Deficit Disorder with Hyperactivity 102
Hyperkinesis 81
Disease 58
Sleep Apnea, Obstructive 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atomoxetine Hydrochloride

Trials by Country

Trials by Country for Atomoxetine Hydrochloride
Location Trials
United States 400
Canada 22
United Kingdom 19
Germany 15
Spain 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atomoxetine Hydrochloride
Location Trials
New York 26
California 24
Florida 18
Ohio 16
Massachusetts 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atomoxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Atomoxetine Hydrochloride
Clinical Trial Phase Trials
Phase 4 59
Phase 3 33
Phase 2/Phase 3 3
[disabled in preview] 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atomoxetine Hydrochloride
Clinical Trial Phase Trials
Completed 133
Recruiting 11
Terminated 10
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atomoxetine Hydrochloride

Sponsor Name

Sponsor Name for Atomoxetine Hydrochloride
Sponsor Trials
Eli Lilly and Company 69
National Institute on Drug Abuse (NIDA) 13
National Institute of Mental Health (NIMH) 9
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atomoxetine Hydrochloride
Sponsor Trials
Other 137
Industry 96
NIH 34
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Colorcon
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.